![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2022/10/11/2531832/0/en/Brooklyn-ImmunoTherapeutics-Announces-Name-Change-to-Eterna-Therapeutics-and-Provides-Corporate-Updates.html
https://www.fiercebiotech.com/biotech/brooklyn-hails-immunotherapy-achieving-primary-objective-just-not-primary-endpoint
https://www.globenewswire.com/news-release/2022/07/26/2485793/0/en/Brooklyn-ImmunoTherapeutics-Announces-Results-of-Phase-2-Study-of-IRX-2-in-Head-and-Neck-Cancer.html
https://www.globenewswire.com/news-release/2022/06/17/2464932/0/en/Brooklyn-ImmunoTherapeutics-Announces-Receipt-of-Nasdaq-Notification-Regarding-Minimum-Bid-Price-Deficiency.html
https://www.globenewswire.com/news-release/2022/06/07/2457573/0/en/Brooklyn-ImmunoTherapeutics-Announces-Board-Changes.html
https://www.globenewswire.com/news-release/2022/05/31/2453125/0/en/Brooklyn-ImmunoTherapeutics-Announces-Changes-to-Executive-Management-Matt-Angel-Ph-D-Appointed-Interim-Chief-Executive-Officer-and-President-Andrew-Jackson-Appointed-Chief-Financi.html
https://www.globenewswire.com/news-release/2022/05/27/2452155/0/en/Brooklyn-ImmunoTherapeutics-Announces-Receipt-of-Notice-from-Nasdaq-Regarding-Delayed-Filing-of-Quarterly-Report-on-Form-10-Q.html
https://www.globenewswire.com/news-release/2022/04/21/2426356/0/en/Brooklyn-ImmunoTherapeutics-Announces-Establishment-of-New-Research-and-Development-Facility-for-Advancement-of-Engineered-Cellular-Medicines.html
https://www.globenewswire.com/news-release/2022/04/15/2423385/0/en/Brooklyn-ImmunoTherapeutics-Announces-Fourth-Quarter-and-Full-Year-2021-Financial-Results.html
https://www.globenewswire.com/news-release/2022/03/09/2400362/0/en/Brooklyn-ImmunoTherapeutics-Announces-Closing-of-12-Million-Private-Placement.html